Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dengue is the most prevalent mosquito-borne viral disease; endemic to 100 countries worldwide, with more than half the world’s populations at-risk AT-752 is a novel, orally administered,...
-
Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19 Trial to Focus on High-Risk Patients at Greatest Risk for Disease Progression ...
-
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Atea management will participate in...
-
Advancing Bemnifosbuvir to Late-Stage Development for COVID-19 Following Meetings with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Emergency Task Force New Data...
-
Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022
BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
-
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
-
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
-
New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo...
-
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
-
BOSTON, March 28, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented two posters highlighting nonclinical data...